Novo Nordisk increased operating profit by 51% in the first nine months of 2015 to DKK 38.3 billion
(Thomson Reuters ONE) -
16% local currency operating profit growth adjusted for the NNIT divestment
Sales increased by 23% in Danish kroner and by 9% in local currencies to DKK
79.1 billion.
* Sales of Victoza(®) increased by 39% (21% in local currencies).
* Ÿ Sales of Levemir(®) increased by 27% (10% in local currencies).
* Ÿ Sales in North America increased by 33% (10% in local currencies).
* Ÿ Sales in International Operations increased by 23% (17% in local
currencies).
* Ÿ Sales in Region China increased by 26% (5% in local currencies).
Gross margin improved by 1.8 percentage points in Danish kroner to 85.4% driven
by a positive currency impact.
Operating profit increased by 51% in Danish kroner and by 26% in local
currencies to DKK 38.3 billion. Adjusted for the DKK 2.4 billion non-recurring
income related to the partial divestment of NNIT, operating profit in local
currencies increased by 16%.
Net profit increased by 33% to DKK 26.6 billion. Diluted earnings per share
increased by 36% to DKK 10.28. Adjusted for the partial divestment of NNIT, net
profit and diluted earnings per share increased by 22% and 24% respectively.
In September, Novo Nordisk announced the US FDA approval of Tresiba(®) and
Ryzodeg(®) 70/30 after the review of the class II resubmission of the New Drug
Applications.
For 2015, sales growth measured in local currencies is still expected to be
7-9%, whereas operating profit growth measured in local currencies is raised by
1 percentage point and now expected to be around 20%.
The preliminary outlook for 2016 in local currencies indicates mid to high
single-digit growth in sales and mid to high single-digit growth in operating
profit adjusted for the non-recurring impact of the partial divestment of NNIT
and the income related to the out-licensing of assets for inflammatory
disorders, both in 2015.
Lars Rebien Sørensen, president and CEO: "We are satisfied with the results of
the first nine months of 2015. Sales growth was primarily driven by Victoza(®)
aided by the high growth of the GLP-1 market. In the third quarter, a
significant milestone was achieved with the US FDA approval of Tresiba(®), and
we look forward to launching Tresiba(®) early 2016."
Contacts for further information
Media:
Katrine Sperling +45 3079 6718 krsp(at)novonordisk.com
Ken Inchausti (US) +1 267 809 7552 kiau(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Daniel Bohsen +45 3079 6376 dabo(at)novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz(at)novonordisk.com
Kasper Veje +45 3075 8519 kpvj(at)novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni(at)novonordisk.com
Company announcement No 65 / 2015
Company announcement No 65 / 2015:
http://hugin.info/2013/R/1962208/715621.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
[HUG#1962208]
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2015 - 07:30 Uhr
Sprache: Deutsch
News-ID 430310
Anzahl Zeichen: 3828
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk increased operating profit by 51% in the first nine months of 2015 to DKK 38.3 billion"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
